Key Takeaways
- • Ken Griffin's Citadel added 2.7 million shares of AbbVie (NYSE: ABBV) in Q2 2026, increasing the hedge fund's stake by 547% to 3.2 million shares worth approximately $798 million, representing 0.46% of Citadel's total portfolio.
- • AbbVie qualifies as a "Dividend King" with 54 consecutive years of annual dividend increases (including its tenure as part of Abbott Labs prior to its 2012 spinoff), currently yielding 2.6% with a quarterly dividend of $1.73 per share as of mid-August.
- • The significant position increase in a defensive, dividend-paying pharmaceutical stock signals a more cautious market posture from Griffin, potentially reflecting concerns about elevated market valuations despite broader Wall Street consensus viewing AbbVie as a buy.
- • Griffin's AbbVie accumulation follows his recent strategic shift to liquidate 80% of assets acquired from AI-focused hedge fund Situational Awareness, indicating a rebalancing away from concentrated technology and artificial intelligence exposure toward more stable, income-generating securities.
Summary
Citadel founder and CEO Ken Griffin substantially increased his hedge fund's exposure to AbbVie during the second quarter of 2026, acquiring 2.7 million additional shares of the pharmaceutical company. This purchase elevated Citadel's total stake to 3.2 million shares valued at approximately $798 million, representing a 547% increase in the fund's position. The stake now comprises roughly 0.46% of Citadel's overall portfolio, making it a material but not dominant holding.
AbbVie's status as a "Dividend King"—a designation reserved for companies with at least 50 consecutive years of dividend increases—underscores the defensive nature of this investment decision. The company has raised its annual payouts for 54 straight years when including its operational history prior to its 2012 spinoff from Abbott Labs. In mid-August 2026, AbbVie distributed a quarterly dividend of $1.73 per share, yielding 2.6% at prevailing share prices. This income stability and predictability make it an attractive holding for institutional investors seeking reliable cash flows.
Griffin's material increase in AbbVie shares reflects a strategic pivot toward more defensive positioning within his portfolio. The timing of this accumulation, occurring as equity markets trade at historically elevated valuation multiples, suggests caution about broader market conditions despite Wall Street consensus regarding AbbVie's attractiveness as a long-term holding. This move aligns with Griffin's recent decision to divest 80% of the assets purchased from the AI-focused hedge fund Situational Awareness—a position he had acquired at a discount following that fund's significant technology and artificial intelligence-related losses. The assets had been integrated into Citadel's Wellington Fund before the reduction. Collectively, these portfolio adjustments indicate a meaningful shift in Griffin's allocation strategy toward stable, income-producing securities and away from concentrated technology and AI sector exposure.
AbbVie's status as a "Dividend King"—a designation reserved for companies with at least 50 consecutive years of dividend increases—underscores the defensive nature of this investment decision. The company has raised its annual payouts for 54 straight years when including its operational history prior to its 2012 spinoff from Abbott Labs. In mid-August 2026, AbbVie distributed a quarterly dividend of $1.73 per share, yielding 2.6% at prevailing share prices. This income stability and predictability make it an attractive holding for institutional investors seeking reliable cash flows.
Griffin's material increase in AbbVie shares reflects a strategic pivot toward more defensive positioning within his portfolio. The timing of this accumulation, occurring as equity markets trade at historically elevated valuation multiples, suggests caution about broader market conditions despite Wall Street consensus regarding AbbVie's attractiveness as a long-term holding. This move aligns with Griffin's recent decision to divest 80% of the assets purchased from the AI-focused hedge fund Situational Awareness—a position he had acquired at a discount following that fund's significant technology and artificial intelligence-related losses. The assets had been integrated into Citadel's Wellington Fund before the reduction. Collectively, these portfolio adjustments indicate a meaningful shift in Griffin's allocation strategy toward stable, income-producing securities and away from concentrated technology and AI sector exposure.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.